ANTI-CD39 – AB598

CD39 is a key enzyme in the tumor microenvironment which degrades Adenosine Triphosphate (ATP), the source of energy inside cells but an immune-activating danger signal outside cells. Inhibiting CD39 may result in an increase in ATP in the tumor microenvironment, which could lead to an enhanced adaptive (T cells) anti-tumor immune response.

Preclinical evidence has demonstrated the rationale for AB598 as a therapeutic intervention for cancer, and clinical development is underway to assess the safety, tolerability and efficacy of this compound in solid tumors.

Arcus is evaluating AB598 alone and in combination with zimberelimab, another investigational molecule in the Arcus portfolio, and chemotherapy for the treatment of advanced solid tumors.